Artelo Biosciences, Inc.
  • About
    • About Artelo
    • Management
    • Board of Directors
    • Scientific Advisors
    • Contact
  • Pipeline
    • Overview
    • ART27.13
    • ART26.12
    • ART12.11
  • Science
    • Overview
    • Publications
  • Investors
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
    • Email Alerts
  • Media
  • Menu Menu
  • Twitter
  • LinkedIn
  • Facebook

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Media
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Email Alerts
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Media
Jan 11, 2022 8:30am EST

Artelo Anticipates Accelerated Clinical Development for ART27.13 Following Its Classification Change in the United Kingdom

Jan 10, 2022 9:00am EST

Artelo Biosciences Leadership to Participate on Endocannabinoid Panel at the H.C. Wainwright BioConnect 2022 Virtual Conference

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
©2025 - Artelo Biosciences, Inc.     info@artelobio.com    |     Terms of Use    |     Privacy Policy
  • Twitter
  • LinkedIn
  • Facebook